Showing 2331-2340 of 5268 results for "".
- Meta-analysis: Early Use of Emollients Can Help Preventing AD in High-risk Infantshttps://practicaldermatology.com/news/meta-analysis-early-use-of-emollients-can-help-preventing-ad-in-high-risk-infants/2461445/Early application of emollients is an effective strategy for preventing atopic dermatitis (AD) in high-risk infants, according to a meta-analysis in the Journal of the European Academy of Dermatology &am
- CeraVe Establishes Fund at Howard University to Address Lack of Diversity in Skincare Clinical Researchhttps://practicaldermatology.com/news/cerave-establishes-fund-at-howard-university-to-address-lack-of-diversity-in-skincare-clinical-research/2461435/To help close the existing racial inequity gap in dermatological research, CeraVe is establishing a fund at Howard University to help its faculty further their expertise and build the infrastructure needed to conduct clinical trials with a focus on skin of color. Located in Washing
- DermTech, Sonora Quest Laboratories Join Forces Expand Access to Melanoma Detection Test in Arizonahttps://practicaldermatology.com/news/dermtech-sonora-quest-laboratories-join-forces-expand-access-to-melanoma-detection-test-in-arizona/2461434/Sonora Quest is the exclusive laboratory offering the DermTech Melanoma Test for all of Arizona. The DermTech Melanoma Test uses a non-invasive Smart Sticker to lift skin cells from the surface of a patient’s skin to be tested for select genomic markers associated with melanoma. I
- Reistone Biopharma's Oral Ivarmacitinib Meets Primary Endpoint in Phase III Study for ADhttps://practicaldermatology.com/news/reistone-biopharmas-oral-ivarmacitinib-meets-primary-endpoint-in-phase-iii-study-for-ad/2461431/Reistone Biopharma’s once daily Ivarmacitinib as monotherapy relieves in improving skin inflammation and itchiness n adults and adolescents with moderate-to-severe, according to a results from thePhase III QUARTZ3 study. The study evaluated the efficacy and safety of once dai
- Supergoop! Founder & CEO Named Ernst & Young LLP’s Entrepreneurs of the Year for 2022https://practicaldermatology.com/news/supergoop-founder-ceo-named-ernst-young-llps-entrepreneurs-of-the-year-for-2022/2461430/Holly Thaggard and Amanda Baldwin of Supergoop! are Ernst & Young LLP’s Entrepreneurs of the Year for 2022. The Entrepreneur of the Year program honors and elevates entrepreneurs who think big and act boldly to change our world for nearly four decades.
- Meet Crown’s ProGen PRP Eclipsehttps://practicaldermatology.com/news/meet-crowns-progen-prp-eclipse/2461417/Crown Aesthetics completed the rebranding of ProGen PRP Advantage, now renamed ProGen PRP Eclipse. ProGen PRP Eclipse is a one-spin system that features 15 mL and 30 mL tubes, yielding 7-15 mL of Platelet Rich Plasma. "Crown's commitment to best-in-class service
- EMA Accepts Filing of MAA for Almirall's Lebrikizumab in ADhttps://practicaldermatology.com/news/ema-accepts-filing-of-maa-for-almiralls-lebrikizumab-in-ad/2461408/The European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for Almirall’s lebrikizumab for the treatment of moderate to severe atopic dermatitis. Lebrikizumab is a novel, investigational, monoclonal antibod
- EWG: FDA Must Ban Oxybenzone in Sunscreen Now!https://practicaldermatology.com/news/ewg-fda-must-ban-oxybenzone-in-sunscreen-now/2461405/The U.S. Food and Drug Administration (FDA) should ban oxybenzone in sunscreens, according to researchers at the Environmental Working Group (EWG). For decades, sunscreen makers have used oxybenzone in their products, despite concerns about its health harms. In 2021, the FDA t
- Kintor Pharma Completes Enrollment and Dosing in Phase I Clinical Trial of AGA, Acne Drughttps://practicaldermatology.com/news/kintor-pharma-completes-enrollment-and-dosing-in-phase-i-clinical-trial-of-aga-acne-drug/2461404/Kintor Pharmaceutical Limited has completed the enrollment and dosing of 120 subjects for its U.S. phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne. Developed through Kintor Pharma's proprietary Proteolysis Targeting Chimera (PROTAC) platfo
- EltaMD Honored in Fast Company Magazine’s 2022 “Brands That Matter” Listhttps://practicaldermatology.com/news/eltamd-honored-in-fast-company-magazines-2022-brands-that-matter-list/2461402/EltaMD has been named to Fast Company’s “Brands that Matter” list for its memorable campaign to increase awareness of skin cancer and how to prevent it. The list honors companies and nonprofits that have had an undeniable impact on business and culture. Skin